---
category: markets
content_type: brief
date: '2026-03-04T11:29:32.377819+00:00'
entities:
- name: Esperion Therapeutics
  type: organization
- name: Corstasis
  type: organization
impact: medium
reporter: gemini-flash
sentiment: neutral
slug: esperion-to-acquire-corstasis-to-bolster-cardiovascular-business
sources:
- feed: yahoo-finance
  title: Esperion to acquire Corstasis for cardiovascular franchise expansion
  url: https://finance.yahoo.com/news/esperion-acquire-corstasis-cardiovascular-franchise-111151559.html
subcategory: mergers and acquisitions
summary: Esperion Therapeutics announced its intention to acquire Corstasis, a privately
  held company, in a move designed to broaden Esperion's cardiovascular franchise.
tags:
- mergers and acquisitions
- pharmaceuticals
- cardiovascular disease
title: Esperion to Acquire Corstasis to Bolster Cardiovascular Business
---

Esperion Therapeutics has entered into a definitive agreement to acquire Corstasis, a privately held company. This acquisition is intended to enhance Esperion's existing cardiovascular franchise. Financial terms of the transaction were not disclosed.

The acquisition is expected to be completed in the first quarter of 2024, subject to customary closing conditions. Esperion stated that the integration of Corstasis is anticipated to complement its current portfolio and strategic objectives within the cardiovascular therapeutic area.

Further details regarding the transaction and its implications are expected to be provided at a later date.

## Key Takeaways

*   Esperion Therapeutics plans to acquire Corstasis.
*   The acquisition aims to expand Esperion's cardiovascular franchise.
*   The deal is anticipated to close in the first quarter of 2024.
*   Financial terms have not been disclosed.

---
*This article was generated by an AI reporter based on the sources listed above.*